167 related articles for article (PubMed ID: 31562719)
1. Efficacy of DPP4i as the Fourth Drug in the Management of Type2 Diabetes Mellitus in Asian Indians Poorly Controlled by Use of at least 3 Oral Antidiabetic Drugs.
Panikar V; Joshi S; Tiwaskar M; Vadgama J; Nasikkar N; Kamat T; Deogaonkar N; Walawalkar S; Sachdev I; Jain C; Modh K; Panikar K; Kulkarni P; Medidar R
J Assoc Physicians India; 2019 Aug; 67(8):60-62. PubMed ID: 31562719
[TBL] [Abstract][Full Text] [Related]
2. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Chen YW; Wang JS; Sheu WH; Lin SY; Lee IT; Song YM; Fu CP; Lee CL
PLoS One; 2017; 12(2):e0171753. PubMed ID: 28182722
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
8. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
Saglietti G; Placentino G; Schellino A
Clin Drug Investig; 2014 Jul; 34(7):513-9. PubMed ID: 24788571
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
Mak WY; Nagarajah JR; Abdul Halim H; Ramadas A; Mohd Pauzi Z; Pee LT; Jagan N
J Pharm Policy Pract; 2020; 13():34. PubMed ID: 32566235
[TBL] [Abstract][Full Text] [Related]
11. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
12. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
14. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
16. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
18. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Nishida Y; Takahashi Y; Tezuka K; Akimoto H; Nakayama T; Asai S
BMC Pharmacol Toxicol; 2020 Apr; 21(1):28. PubMed ID: 32317005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]